Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA ‐76 as a Novel Analgesic in Male Rats and Mice
Pharmacology Research & Perspectives · 2026-12 · 14 (6)
DOI: 10.1002/prp2.70342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 05.11.2026. Verfasst von Kristen L Woodhouse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Analgesics, Receptors, Lysophosphatidic Acid, Hyperalgesia, Neuralgia. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Clinically used analgesics such as gabapentinoids and opioids have limited efficacy and adverse effects like abuse liability, and there is a dire need for novel analgesics with improved safety profiles. Since lysophosphatidic acid can induce neuropathic pain in rodents, LPA receptor antagonists have been investigated as potential analgesics. This study examined the antiallodynic, reinforcing, and cognitive effects of lysophosphatidic acid receptor 5 (LPA5) antagonist, RLPA‐76, using male rodents. Three preclinical pain models were used: spinal nerve ligation (SNL), chronic constriction injury (CCI), and complete Freund's adjuvant (CFA), where mechanical hypersensitivity was measured using von Frey filaments. Rats with a prior history of self‐administering methamphetamine were allowed to self‐administer RLPA‐76 to assess abuse potential. To determine whether RLPA‐76 had any cognitive effects, rodents were tested using novel object recognition (NOR) and T‐maze. Platelet aggregation and radioligand binding screens were performed to evaluate drug specificity. RLPA‐76 attenuated mechanical allodynia in SNL mice, CCI rats, and CFA rats. Rats self‐administered RLPA‐76 no more than vehicle, RLPA‐76 pretreated mice performed like vehicle‐treated mice in NOR, and CFA rats pretreated with RLPA‐76 alternated to a similar extent to vehicle‐pretreated rats in the T‐maze. In vitro screens found that RLPA‐76 lacked concentration‐dependent effects on human platelets and had significant binding at only 1 of 44 targets. In conclusion, RLPA‐76 was antiallodynic in multiple preclinical pain models and had no reinforcing or cognitive effects at analgesic doses in male rodents, supporting the therapeutic potential of RLPA‐76 as a novel analgesic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
- Research Triangle Institute, Research Triangle Park, North Carolina, USA.
ORCID-Profile: Kristen L Woodhouse, Maowei Wang, Olatunbosun Adeoke, Yanan Zhang, Jun-Xu Li
Förderung
- NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Woodhouse, K. L., Wang, M., Anupindi, S. G. B. V., Adeoke, O., Zhang, D., Zhang, Y., & Li, J. X. (2026). Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA ‐76 as a Novel Analgesic in Male Rats and Mice. Pharmacology Research & Perspectives, 14(6). https://doi.org/10.1002/prp2.70342
Vancouver
Woodhouse KL, Wang M, Anupindi SGBV, Adeoke O, Zhang D, Zhang Y, et al. Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA ‐76 as a Novel Analgesic in Male Rats and Mice. Pharmacology Research & Perspectives. 2026;14(6). doi:10.1002/prp2.70342
BibTeX
@article{Woodhouse2026,
author = {Woodhouse, Kristen L and Wang, Maowei and Anupindi, Sai Ganesh Balaji Venkata and Adeoke, Olatunbosun and Zhang, Dehui and Zhang, Yanan and Li, Jun-Xu},
title = {Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA ‐76 as a Novel Analgesic in Male Rats and Mice},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {6},
doi = {10.1002/prp2.70342}
}
EUVIMED